- Home
- ARBE vs CGEN Comparison
ARBE vs CGEN Comparison
Compare ARBE & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBE
- CGEN
- Stock Information
- Founded
- ARBE 2015
- CGEN 1993
- Country
- ARBE Israel
- CGEN Israel
- Employees
- ARBE N/A
- CGEN N/A
- Industry
- ARBE EDP Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARBE Technology
- CGEN Health Care
- Exchange
- ARBE Nasdaq
- CGEN Nasdaq
- Market Cap
- ARBE 124.2M
- CGEN 135.6M
- IPO Year
- ARBE N/A
- CGEN 2000
- Fundamental
- Price
- ARBE $1.08
- CGEN $1.47
- Analyst Decision
- ARBE Buy
- CGEN Strong Buy
- Analyst Count
- ARBE 2
- CGEN 1
- Target Price
- ARBE $1.75
- CGEN $4.00
- AVG Volume (30 Days)
- ARBE 1.5M
- CGEN 268.4K
- Earning Date
- ARBE 05-21-2025
- CGEN 05-19-2025
- Dividend Yield
- ARBE N/A
- CGEN N/A
- EPS Growth
- ARBE N/A
- CGEN N/A
- EPS
- ARBE N/A
- CGEN N/A
- Revenue
- ARBE $768,000.00
- CGEN $27,864,000.00
- Revenue This Year
- ARBE $398.05
- CGEN $11.81
- Revenue Next Year
- ARBE $366.67
- CGEN $28.37
- P/E Ratio
- ARBE N/A
- CGEN N/A
- Revenue Growth
- ARBE N/A
- CGEN N/A
- 52 Week Low
- ARBE $0.85
- CGEN $1.13
- 52 Week High
- ARBE $5.09
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- ARBE 39.88
- CGEN 49.50
- Support Level
- ARBE $1.03
- CGEN $1.13
- Resistance Level
- ARBE $1.15
- CGEN $1.35
- Average True Range (ATR)
- ARBE 0.09
- CGEN 0.11
- MACD
- ARBE 0.04
- CGEN 0.03
- Stochastic Oscillator
- ARBE 76.67
- CGEN 85.00
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, USA, and others.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.